PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT

BACKGROUND: Ras/Raf/MEK/ERK pathway activation is the primary driver of most pediatric low-grade gliomas (LGG), the most common brain tumor in children. Unresectable LGG are associated with multiple recurrences and significant long-term morbidity. MEK162 is an orally bioavailable inhibitor of MEK1/2...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Robison, Nathan, Pauly, Jasmine, Malvar, Jemily, Filbin, Mariella, de Mola, Rebecca Loret, Dorris, Kathleen, Bendel, Anne, Bowers, Daniel, Bornhorst, Miriam, Gauvain, Karen, Leary, Sarah, MacDonald, Tobey, Gardner, Sharon, Reddy, Alyssa, Diaz, Patricia, Tan, Yi Juin, Sinai, Claire, Davidson, Tom, Ullrich, Nicole, Margol, Ashley, Dhall, Girish, Borchert, Mark, Ligon, Keith, Sposto, Richard, Kieran, Mark
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692641/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.765
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky